Successful treatment of metastatic clear cell carcinoma with nivolumab in a patient receiving dialysis treatment
Successful treatment of metastatic clear cell carcinoma with nivolumab in a patient receiving dialysis treatment
复制标题
使用纳武单抗成功治疗接受透析治疗的患者的转移性透明细胞癌
DOI：
10.1111/iju.13420
复制
发表时间：
2017
影响因子：
2.6
通讯作者：
Kazuki Kobayashi
中科院分区：
文献类型：
--
作者：
Tadashi Tabei;I. Natsume;Kazuki Kobayashi
纳武利尤单抗对接受透析治疗的患者的疗效和安全性尚未确定。在本文中，我们描述了一名接受透析的患者，该患者成功接受了nivolumab作为转移性肾细胞癌的第七线治疗。在开始纳武利尤单抗治疗前，患者出现了由阻塞左中间支气管的病变引起的呼吸不适，该病变起源于气管分叉后的转移性淋巴结。纳武利尤单抗治疗开始后4周，患者症状显著改善，根据支气管镜检查，闭塞消失。纳武利尤单抗的有效性和安全性已持续6个月。很少有病例将纳武利尤单抗用于透析患者。在这种情况下，nivolumab被给予透析患者，并且它导致了显着的改善，没有任何不良事件。
The efficacy and safety of nivolumab for patients receiving dialysis treatment has not been established yet. Herein, we describe a patient on dialysis successfully treated with nivolumab as seventh‐line therapy for metastatic renal cell carcinoma. Before initiating nivolumab, he had respiratory discomfort induced by a lesion occluding the left intermediate bronchus that originated from the metastatic lymph node behind the tracheal bifurcation. Four weeks after nivolumab was initiated, his symptom remarkably improved, and the occlusion disappeared according to the bronchoscopy examination. The effectiveness and safety of nivolumab has continued for 6 months. There are few cases in which nivolumab has been given to patients on dialysis. In the present case, nivolumab was given to a patient on dialysis, and it resulted in a remarkable improvement without any adverse events.